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Abstract
Objectives: Many countries use faecal immunochemical testing (FIT) to screen for colorectal cancer. There is increasing
evidence that faecal microbiota play a crucial role in colorectal cancer carcinogenesis. We assessed the possibility of
measuring faecal microbial features in FIT as potential future biomarkers in colorectal cancer screening.
Methods: Bacterial stability over time and the possibility of bacterial contamination were evaluated using quantitative
polymerase chain reaction analysis. Positive FIT samples (n¼ 200) of an average-risk screening cohort were subsequently
analysed for universal 16S, and bacteria. Escherichia coli (E. coli), Fusobacterium nucleatum (F. nucleatum), Bacteroidetes and
Faecalibacterium prausnitzii (F. prausnitzii) by qPCR. The results were compared with colonoscopy findings.
Results: Faecal microbiota in FIT were stably measured up to six days for E. coli (p¼ 0.53), F. nucleatum (p¼ 0.30),
Bacteroidetes (p¼ 0.05) and F. prausnitzii (p¼ 0.62). Overall presence of bacterial contamination in FIT controls was low.
Total bacterial load (i.e. 16S) was significantly higher in patients with colorectal cancer and high-grade dysplasia
(p¼ 0.006). For the individual bacteria tested, no association was found with colonic lesions.
Conclusions: These results show that the faecal microbial content can be measured in FIT samples and remains stable for six
days. Total bacterial load was higher in colorectal cancer and high-grade dysplasia. These results pave the way for further
research to determine the potential role of microbiota assessment in FIT screening.
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Key summary
What is the established knowledge on this subject?
. Faecal immunochemical tests are used worldwide in colorectal cancer screening.
. There is increasing evidence that the gut microbiota play a crucial role in colorectal cancer carcinogenesis.
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What are the signiﬁcant and/or new ﬁndings of this study?
. The gut microbiota can be measured in faecal immunochemical test samples.
. Individual microbial features remain relatively stable in faecal immunochemical test samples for up to six
days
. Screenees with high-grade dysplasia and colorectal cancer have a higher load of total universal 16S in their
faecal immunochemical test samples.
Introduction
Colorectal cancer (CRC) is a major cause of cancer-
related morbidity and mortality.1 The aetiology of
CRC is complex and not yet completely understood.
There is increasing attention for the gut microbiota
and its role in colorectal carcinogenesis.2–4 It is estimated
that at least 20%, perhaps more, of the cancer burden
worldwide can be attributed to microbial agents.5
An association between CRC and speciﬁc faecal bac-
teria has already been reported a long time ago.6 In a
small Dutch study of 12 patients with Streptococcus
bovis bacteraemia, CRC was diagnosed in eight and
gastric cancer in one patient.7 CRC appears to have a
complex aetiology with potential aetiological contribu-
tion of multiple bacterial species playing diﬀerent
roles.3,4,8 Most gut bacteria cannot easily be cultivated,
yet sequencing of bacterial DNA following polymerase
chain reaction (PCR) allows for the identiﬁcation of the
composition of the faecal microbiota. Evidence to date
suggests that inﬂammatory processes triggered by
enterotoxigenic bacteria can contribute to CRC devel-
opment by facilitating DNA damage in intestinal epi-
thelial cells.4,9 The ensuing accumulation of genetic
lesions can contribute to oncogenesis along the aden-
oma–carcinoma sequence. Several studies have shown
that the bacterial composition of malignant lesions dif-
fers from that of surrounding normal tissue.4,10,11
While most previous research has focused on the unra-
velling of the complex microbial composition in CRC
and the role of the gut microbiota in the pathogenesis
of CRC, it is of interest to see whether altered bacterial
presence may be valuable in improving screening
strategies.
In the past decade, an increasing number of coun-
tries have embarked on CRC screening. Many of those
use faecal immunochemical tests (FITs) as their screen-
ing method.12 FITs rely on the measurement of trace
amounts of blood from neoplastic lesions. However,
not all lesions bleed (e.g. serrated adenomas), and con-
versely, occult blood can be detected in faecal samples
of healthy individuals.13 In spite of high participation
rates and a relatively high sensitivity for CRC of 75–
85% depending on the cut-oﬀ used, the sensitivity of
FIT for detection of advanced adenomas is much lower
and generally ranges below 50%.14,15 For this reason
there is an urgent need for additional markers to
increase FIT sensitivity without losing its speciﬁcity,
as the latter is of crucial importance in a screening set-
ting. Investigation of faecal bacterial features could
present one such possible additional marker.16 Hence,
it would be of great interest to detect bacterial features
in the test materials of FIT screenees, which would pre-
clude additional material collection from screenees.
Therefore, the aim of our study was to evaluate the
possibility of measuring faecal microbiota in FIT in
relation to endoscopic ﬁndings, to evaluate their stabil-
ity over time and to assess the eﬀect of potential bac-
terial contaminants in downstream PCR analysis.
For this proof of principle, we have selected four diﬀer-
ent bacterial markers for quantitative PCR (qPCR)
analysis: suspected driver bacteria of the
Enterobacteriaceae (Escherichia coli; E. coli),
Bacteroidetes-species, the most often associated CRC
bacterium Fusobacterium nucleatum (F. nucleatum)
and the anti-inﬂammatory Clostridiaceae
Faecalibacterium prausnitzii (F. prausnitzii), which was
described to be less prevalent in CRC patients.17–24 In
addition, taxonomic proﬁling was carried out for six
pooled samples from patients with diﬀerent endoscopy
outcomes to evaluate the feasibility of using FIT ﬂuid
for future 16S rRNA gene sequencing purposes.
Methods
Patients, FIT screening and data collection
Details about the design of this ongoing population-
based FIT CRC screening programme have been
described previously.25 In short, demographic data of
all individuals between 50 and 74 years old living in the
southwest of The Netherlands were randomly obtained
from municipal population registers and were invited
for FIT screening biennially. At present, four rounds of
FIT screening have taken place. For this study only
FIT samples of the end of the third and beginning of
the fourth screening round were used, aiming for a total
of 200 FITs to be included. Recruitment of these third
and fourth screening rounds took place between
February 2013 and August 2014. In the third screening
round all invitees received the OC-sensor (Eiken,
Japan). In the fourth screening round invitees were
randomized between the OC-sensor and FOB-Gold
(Sentinel, Italy). Participants were instructed to send
the FIT sample within one day after collection and to
keep the FIT sample in the refrigerator until sending it
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to the laboratory. A cut-oﬀ of 10 mgHb/g faeces was
used to refer the screenee for a colonoscopy within four
weeks. All colonoscopies were performed by gastro-
enterologists with an experience based on at least
1000 colonoscopies. All lesions were evaluated by
trained gastrointestinal pathologists according to the
Vienna criteria.26 Advanced adenomas were deﬁned
as an adenoma with a diameter 10mm, and/or with
a 25% villous component, and/or high-grade dyspla-
sia (HGD). Advanced neoplasia included advanced
adenoma and CRC, with the most advanced lesion
used for analysis. Serrated polyps were deﬁned as ser-
rated adenomas (with our without dysplasia) and
hyperplastic polyps. For this study only FIT-positive
screenees were included.
Bacterial quantitative analysis
After occult blood measurement, FIT samples were
stored at 20C until analysis. DNA was isolated
from FIT liquid by Wizard Genomic DNA
Puriﬁcation kit (Promega, Leiden, The Netherlands)
with modiﬁcations. Information on primers, PCR and
qPCR analyses can be found in Supplementary
Material ﬁle 1 online.
Microbial stability and contamination in FIT
For analysis of the stability of the microbial content of
FIT over time, seven FITs from stool samples with
(n¼ 2) and without blood (n¼ 5) of healthy volunteers
were collected and stored at 20C immediately, or
after 24, 48, 72, 96, 120 and 144 h in order to mimic
FIT transit time. DNA was isolated from all samples
upon thawing and the presence of E. coli, F. nucleatum,
Bacteroidetes, F. prausnitzii and universal bacterial 16S
was detected by PCR and qPCR as described above. F.
nucleatum was below detection level in all FIT samples
of our healthy donors and could not be included in the
analysis. To test for unintentional bacterial contamin-
ation, FIT controls with and without blood but not
containing faeces underwent the same procedure for
comparison with FIT with blood and faecal material.
16S rRNA gene sequencing pilot
To determine the feasibility of using FIT material for
16S rRNA gene sequencing, a pilot was conducted
using six diﬀerent pooled DNA samples from patients
with the following conditions: 1) no endoscopic ﬁnd-
ings, 2) tubular adenoma, 3) HGD, 4) CRC, 5) sessile
adenoma and 6) hyperplastic polyp. All samples were
shipped on dry ice to the Macrogen Institute in Seoul,
Korea. The V3-4 region of the 16S rRNA gene was
ampliﬁed and sequenced on the Illumina MiSeq
platform. The 16S rRNA gene sequencing data was
subsequently processed using the SILVA database for
taxonomic proﬁling at genus level, allowing for the
global assessment of the bacterial presence of our
selected markers in FIT material.
Statistical analysis
Descriptive data were reported as proportions or means
with the standard deviation. For non-normally distrib-
uted data the median and interquartile range (IQR)
were given. Chi-square tests were used to analyse cat-
egorical data; continuous data were analysed using
Student’s t-tests or one-way analysis of variance.
Linear regression analysis was used to assess bacterial
load and transit time. Correction for multiple testing
was done according to Bonferroni resulting in a two-
sided p-value of <0.01 that was considered to be stat-
istically signiﬁcant. Statistical analysis was performed
using IBM SPSS version 21.0.
Results
FIT screenees
A total of 200 samples from FIT positive screenees were
collected. Of these, 20 samples had to be discarded for
various reasons (e.g. because multiple samples from the
same screenee were included, because a sample was
misclassiﬁed or because pathology outcome was miss-
ing), resulting in 180 samples available for analysis of
microbial content. These included 119 OC-sensor tests
(66%) and 61 FOB-Gold tests (34%). Of those, 56%
were male with a median age of 64 years (IQR 58–69
years). Median faecal Hb concentration was 21 mg Hb/g
faeces (IQR 13–55mg Hb/g faeces). All screenees
included in this study underwent complete colonoscopy
and in 31% (n¼ 55) patients advanced neoplasia was
detected, of whom ﬁve were diagnosed with CRC. All
colonoscopy ﬁndings are described in Table 1.
Stability microbiota in FIT over time and bacterial
contaminants
Transit time of the FIT from screenee to the laboratory
could potentially aﬀect the microbial composition
detected. Although growth of anaerobic bacteria is
not expected, and FIT buﬀer contains bacteriostatic
sodiumazide, degradation of bacterial DNA might
occur. Therefore, we ﬁrst analysed the stability of the
bacterial composition in FIT. Universal bacterial 16S,
Bacteroidetes, F. prausnitzii and E. coli DNA was con-
sistently detected by qPCR, with no signiﬁcant loss in
detection levels for up to 144 h in FIT positive
(Figure 1(a)) and FIT negative (Figure 1(b) and (c))
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samples. Microbial contamination did not inﬂuence our
results as indicated by relatively low levels of bacterial
contamination detected in FIT controls (Figure 2). The
16S and individual bacterial marker levels in FIT ﬂuid
without faecal content were similar to water controls
and several times lower than FIT ﬂuid containing faecal
material.
The average time between faecal sampling by the
screenee and analysis at the laboratory (i.e. transit
time) was one day (IQR 1–2 days), with 91% of
FITs arriving at the laboratory within two days
after sampling. For all screenees the correlation
between absolute copy number of the four bacteria
and transit time were evaluated (Figure 3). No sig-
niﬁcant decrease in faecal microbiota was seen in up
to six days for E. coli (p¼ 0.53), F. nucleatum
(p¼ 0.30), Bacteroidetes (p¼ 0.05) and F. prausnitzii
(p¼ 0.62; Figure 3).
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Figure 1. Stability of bacterial composition over time for faecal immunochemical testing (FIT) positive (n¼ 2) (a) and FIT negative
specimens (n¼ 5) (b) and (c). This has been depicted for universal 16S and specific markers including Bacteroidetes, Faecalibacterium
prausnitzii and Escherichia coli. Bacterial composition remained stable up to at least 144 h.
Table 1. Primer sequences used in this study.
Bacterium Sequence (5’–3’) Product size Reference
Universal 16S Forward CGGTGAATACGTTCCCGG 145 1, 9–12
Reverse TACGGCTACCTTGTTACGACTT
Fusobacterium nucleatum Forward CTTAGGAATGAGACAGAGATG 140 2, 13
Reverse TGATGGTAACATACGAAAGG
Escherichia coli Forward CATGCCGCGTGTATGAAGAA 96 3, 4, 14
Reverse CGGGTAACGTCAATGAGCAAA
Bacteroidetes Forward GGTGTCGGCTTAAGTGCCAT 140 5, 6, 15
Reverse CGGACGTAAGGGCCGTGC
Faecalibacterium prausnitzii Forward GATGGCCTCGCGTCCGATTAG 198
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Figure 3. Transit time (interval between faecal sampling and arrival of the faecal immunochemical testing (FIT) specimen at the
laboratory) and absolute copy number/gram faecal immunochemical test for Escherichia coli (a), Fusobacterium nucleatum (b),
Bacteroidetes (c), Faecalibacterium prausnitzii (d).
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Figure 2. Quantitative polymerase chain reaction (qPCR) assessment of unintentional bacterial contamination. Faecal immunochemical
testing controls in either the presence or the absence of occult blood and/or faecal material were tested for 16S, Bacteroidetes,
Faecalibacterium prausnitzii and Escherichia coli. Water controls were concurrently processed for qPCR analysis.
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Microbiota in FIT and findings at colonoscopy
For all samples, copy number per gram (copy nr./g)
FIT liquid was calculated for the total number of bac-
teria (i.e. 16S) and the four predeﬁned bacteria. A sig-
niﬁcant diﬀerence was seen for 16S, with increasing
abundance of total bacterial content in screenees with
high-grade dysplasia and CRC (p¼ 0.006; Figure 4(a)).
Signiﬁcant diﬀerences between the groups were seen for
the copy nr./g E. coli (p¼ 0.05; Figure 4(b)). Post hoc
testing revealed that in particular patients with tubular
and villous adenoma showed lower levels of E. coli,
albeit not signiﬁcant (p¼ 0.07). For F. nucleatum, F.
prausnitzii and Bacteroidetes, no association was
observed between the presence of the bacteria and
any particular lesion (Supplementary Figure 1). No sig-
niﬁcant association between amounts of bacteria and
presence of advanced neoplasia was observed
(Supplementary Figure 2).
To correct for potential diﬀerences in amount of
faecal matter in the FIT, the bacteria were also calcu-
lated relative to the total bacterial presence as deter-
mined by universal 16S (copy nr./g of 16S). No
signiﬁcant diﬀerences were found when evaluating FIT
microbiota according to all colonoscopy ﬁndings,
including CRC, for E. coli (p¼ 0.97), F. nucleatum
(p¼ 0.98), Bacteroidetes (p¼ 0.15) and F. prausnitzii
(p¼ 0.91; Figure 5). In addition, no signiﬁcant diﬀer-
ences in microbiota were found between screenees with
and without advanced neoplasia (E. coli p¼ 0.30;
F. nucleatum p¼ 0.55; Bacteroidetes p¼ 0.12; F. praus-
nitzii p¼ 0.93; Figure 6). When evaluating FIT micro-
biota according to location of the most advanced lesion
(i.e. distal vs. proximal), again no signiﬁcant diﬀerences
were seen for all four bacteria (Supplementary Figure 3).
16S rRNA gene sequencing of pooled samples
Although it is well known that the overall bacterial
abundance in FIT material is relatively low compared
with stool specimens, 16S rRNA gene sequencing data
were generated for all six pooled DNA samples from
patients with respectively: 1) no endoscopic ﬁndings, 2)
tubular adenoma, 3) HGD, 4) CRC, 5) sessile adenoma
and 6) hyperplastic polyp. Taxonomic classiﬁcation
indicated that Bacteroidetes in addition to genus
Faecalibacterium (with regard to F .prausnitzii) and
family Enterobacteriaceae (with regard to E. coli)
were present in all samples (Supplementary Figure 4).
Genus Fusobacterium (with regard to F. nucleatum) was
detected in the pooled DNA samples from tubular
adenomas, suggesting that this lower abundant bacter-
ial marker is present in FIT material. More import-
antly, these ﬁndings conﬁrm the ability to use FIT
specimens for qPCR analysis as well as future 16S
rRNA sequencing purposes.
Discussion
Our results show that faecal microbial DNA can be iso-
lated from FIT samples and remains stable for up to six
days. The inclusion of FIT controls in qPCR analysis
allowed the assessment of bacterial contamination
which appeared to be of minimal impact as the detected
levels were similar to water controls. When the qPCR
ﬁndings were put against the endoscopic ﬁndings, screen-
ees with HGD and CRC had a higher load of total uni-
versal 16S. With respect to speciﬁc microbial features, no
relation was found between numbers of speciﬁc bacteria
and colonoscopy ﬁndings relative to total 16S, except
that numbers of E. coli were reduced in patients with
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Figure 4. Copy number per gram faecal immunochemical testing liquid for 16S (a) and Escherichia coli (b) according to colonoscopy
outcomes.
nr.: number; SP: serrated polyp; TA: tubular adenoma; TVA: (tubulo)villous adenoma; HGD: high grade dysplasia; CRC: colorectal cancer
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tubular and villous adenoma. With regard to location of
the lesion, no diﬀerences were found between a lesion in
the distal or proximal colon and number of faecal bac-
teria observed.
E. coli and Bacteroidetes species have been suggested
to promote inﬂammation, driving the colorectal epithe-
lium to a carcinogenic state.18,20,21 This state of inﬂam-
mation and dysbiosis gives room for opportunistic
bacteria, such as F. nucleatum, to further induce
carcinogenesis, whereas anti-inﬂammatory bacteria
such as F. prausnitzii may be ‘crowded out’.4,21
Consequently various bacteria take part in the process
of carcinogenesis, with many of these bacteria being
variably present during carcinogenesis.4 This could
explain why lower concentrations of E. coli were
found in tubular and villous adenomas, although
screenees with normal colonoscopy and those with
CRC had similar concentrations. Our ﬁndings did not
support a role for E. coli and Bacteroidetes as
additional biomarkers in FIT samples to identify FIT-
positive screenees at risk of carrying advanced aden-
omas. Previous studies have suggested a role for F.
nucleatum in CRC, in particular, the detection of sessile
serrated lesions, with the mucus cap on these lesions
suggested as a cause for the high levels of F. nuclea-
tum.19 Additional detection of sessile serrated lesions
would be especially valuable in FIT screening, as FIT
is known to have a poor sensitivity for these lesions.27
However, our results did not show any association
between F. nucleatum and hyperplastic polyps or ser-
rated lesions compared with other neoplasia or a
normal colon (p¼ 0.82; data not shown). This could
be because F. nucleatum is not sensitive enough by
itself as a biomarker in a screening setting due to over-
abundance in healthy subjects.28
We found that faecal microbial DNA remained
stable over six days, which is in line with ﬁndings
from a previous study comparing diﬀerent collection
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Figure 5. Absolute copy number per 16S and most advanced colonoscopy finding* for Escherichia coli (a), Fusobacterium nucleatum (b),
Bacteroidetes (c) and Faecalibacterium prausnitzii (d).
nr.: number; *SP: serrated polyp; TA: tubular adenoma; TVA: (tubulo)villous adenoma; HGD: high grade dysplasia; CRC: colorectal cancer
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methods of faeces, including FIT.29 Furthermore, one
other study has looked speciﬁcally at isolating bacterial
DNA from FIT samples.30 Its ﬁndings are in line with
ours showing that faecal material contained in FIT
sampling is suﬃcient to perform microbiota character-
ization and is representative of bacterial ﬁndings in a
full stool sample.
Most other studies regarding the role of the micro-
biome in colorectal carcinogenesis have looked specif-
ically at the microbiome at and around the tumour-site
and it is conceivable that a faecal sample obtained by
FIT is not representative of onsite mucosal dysbio-
sis.31,32 However, microbiota on mucosa retrieved
during colonoscopy or surgery could be inﬂuenced by
the bowel preparation that all patients undergo prior to
the intervention. Furthermore, most of these studies
had a case–control design and were thus prone to over-
estimation of diagnostic performance.33 To date, a
small number of studies have looked at the faecal
microbiome in FIT screenees, showing a diﬀerence in
overall faecal microbiome between healthy patients and
patients with colorectal adenomas.34,35 Two of these
studies analysed the microbiota in full stool samples
and not in the FIT samples themselves, making com-
parison with our data complex. However, a full stool
sample may ask for a considerable eﬀort from the
screenee, making the design undesirable in a screening
setting as it might hamper participation rates. Baxter
et al. used 16S sequencing of stool samples to identify a
microbiota-based model to predict colonic lesions and
subsequently showed that this model also worked on
DNA isolated from FITs indicating that FIT ﬂuid may
indeed provide additional biomarkers for CRC detec-
tion.30,35 While 16S rRNA gene sequencing data may
allow a more in depth analysis of the microbiome as
seen in patients with diﬀerent degrees of intestinal
malignancy, its use for diagnostic purposes of individ-
ual patients may be cumbersome. Furthermore, in our
pilot study, it was not possible to retrieve detailed taxo-
nomic information on species level as, with a limited
sequencing depth, 16S rRNA gene sequencing did not
pick up speciﬁc markers at species level such as
(c) (d)
(a) (b)
1.0×10–07
1.0×10–05
1.0×10–04
1.0×10–03
1.0×10–02
1.0×10–01
1.0×10–06
1.0×1000
1.0×1001
F. 
nu
cle
at
um
 
(co
py
 n
r./
16
S)
1.0×10–00
1.0×10–05
1.0×1000
1.0×1005
E.
 
co
li (
co
py
 n
r./
16
S)
Ba
ct
er
oi
de
te
s 
 
(co
py
 n
r./
16
S)
0.0001
0.001
0.01
0.1
1
10
100
1000
p = 0.30
p = 0.12
p = 0.55
1.0×1003
1.0×1005
1.0×1008
1.0×1007
1.0×1008
1.0×1004
1.0×1009
1.0×1010
F. 
pr
au
sn
itz
ii (
co
py
 n
r./
16
S)
p = 0.93
No
 AN AN
No
 AN AN
No
 AN AN
No
 AN AN
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F. nucleatum. For implementation in diagnostic labora-
tories, it might be preferable to ﬁnd microbial bio-
markers which may be identiﬁed in FIT by readily
available PCR techniques rather than 16S or metage-
nomic sequencing eﬀorts. However, with current litera-
ture not agreeing on the actual absence or presence of
bacteria featured in colonic lesions, identifying the right
biomarker to investigate is key.
The strengths of our study include the fact that all
FIT samples were retrieved from a population-based
CRC screening cohort, consisting of average risk screen-
ees, resulting in a high external validity. Also, as gut
microbiota were measured in FIT samples, no additional
stool samples were required from the participants. It is
the ﬁrst study comparing microbial features between
previously untreated patients across the adenoma-to-car-
cinoma range, including all the diﬀerent stages of malig-
nancy. Furthermore, we included FIT samples that
tested positive for occult blood for both lesions and
non-lesions, precluding the possibility of a bias intro-
duced by potential microbe–blood interactions.36 In
order to appreciate our results, some limitations also
need to be addressed. At present, the exact pathway
and role of the gut micriobiota are unknown. Since no
known common suspects have been consistently identi-
ﬁed, we have selected four bacteria for this qPCR study,
but the inclusion of other bacteria could be of more
interest in the future. As only FIT-positive subjects
underwent colonoscopy, it was not possible to evaluate
prime indicators of diagnostic performance, including
sensitivity, speciﬁcity and the area under the receiver-
operating curve. However, we considered analysis of
only positive FITs justiﬁed as, in the end, this is the
population for whom identiﬁcational biomarkers
would be of beneﬁt to avoid unnecessary endoscopic
screening. Furthermore, we used the most advanced
lesion detected during colonoscopy, while screenees
sometimes have more than one lesion. The presence of
multiple lesions could theoretically lead to our ﬁndings
being an underestimation of the relation between faecal
microbiome and colonic neoplasia, although for screen-
ing purposes subjects at highest risk (i.e. with advanced
neoplasia) are of most interest. Another important limi-
tation is the small sample size and the absence of nega-
tive controls in the 16S rRNA gene sequencing pilot.
PCR analysis indicates that, while orders of multitude
lower, contaminants will be present during isolation and
ampliﬁcation of DNA from FIT ﬂuids. Although the
markers of choice were detectable in the pooled samples,
which shows their feasibility to use for qPCR purposes,
future studies should incorporate negative controls to
conﬁrm the detection of biological relevant signals and
to control for bacterial contamination.
In conclusion, our results illustrate that the gut
microbial markers can be stably measured in FIT
samples in CRC screening, with a higher total bacterial
load for CRC and high-grade dysplasia. The need to
increase FIT sensitivity, especially for advanced aden-
omas, remains of evident importance and further stu-
dies should be conducted to determine the role of
microbiota, and preferably speciﬁc biomarkers, in FIT.
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